NASDAQ:BFRA Biofrontera (BFRA) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free BFRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.51▼$2.7850-Day Range$2.50▼$3.6052-Week Range$2.09▼$7.54Volume7,263 shsAverage Volume27,512 shsMarket Capitalization$73.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biofrontera alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Biofrontera Stock (NASDAQ:BFRA)Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report BFRA Stock News HeadlinesApril 4, 2024 | msn.comLeverkusener Pharma-AG: Warum Biofrontera sich weiter von seinem Gründer absetztApril 4, 2024 | finanznachrichten.deBiofrontera plant eine FinanzierungsrundeApril 25, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 19, 2024 | finance.yahoo.comQ4 2023 Biofrontera Inc Earnings CallMarch 15, 2024 | investorplace.comBFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023February 28, 2024 | morningstar.comBiofrontera Inc BFRIFebruary 20, 2024 | marketwatch.comBiofrontera Up 56% After Revised Supply Agreement, Private Placement NewsFebruary 20, 2024 | msn.comWhat's Going On With Biofrontera Stock?April 25, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.February 6, 2024 | msn.comBiofrontera FDA Review Advances Ameluz® Dosage ExpansionFebruary 5, 2024 | finanznachrichten.deBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz to Permit Up to Three Tubes Per UseFebruary 5, 2024 | stockhouse.comBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per UseFebruary 5, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: Ameluz® erhält Zulassungserweiterung für Anwendung mit künstlichem Tageslicht in der EU und in GroßbritannienFebruary 3, 2024 | msn.comBiofrontera’s Pre-Funded Warrants Fully Exercised by InvestorFebruary 3, 2024 | msn.comBiofrontera Amends Agreement, Adjusts Payment ScheduleFebruary 2, 2024 | msn.comWhy Is Biofrontera (BFRI) Stock Down Today?January 26, 2024 | msn.comBiofrontera Receives Extension to Regain Nasdaq ComplianceJanuary 24, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: EMA genehmigt optimierte Formulierung von Ameluz®January 11, 2024 | finanznachrichten.deBiofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023January 9, 2024 | msn.comZulassung erweitert: Wie Biofrontera auf dem europäischen Markt durchstarten willJanuary 4, 2024 | marketwatch.comBiofrontera Shares Rise on Maruho SettlementNovember 16, 2023 | morningstar.comBiofrontera AG B8FAugust 31, 2023 | finanznachrichten.dePTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN HALBJAHRES 2023August 29, 2023 | finance.yahoo.comBiofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer AccountsAugust 11, 2023 | msn.comBiofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2023 | finance.yahoo.comBiofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 10, 2023 | finanznachrichten.deBiofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz-PDT for the Treatment of Basal Cell CarcinomaSee More Headlines Receive BFRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/24/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRA CUSIPN/A CIK1712641 Webwww.biofrontera.com Phone(921) 487-6320Fax49-02-1487-6320Employees138Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net Margins-59.44% Pretax MarginN/A Return on Equity-93.31% Return on Assets-24.02% Debt Debt-to-Equity Ratio0.13 Current Ratio1.26 Quick Ratio1.13 Sales & Book Value Annual Sales$36.19 million Price / Sales2.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.43Miscellaneous Outstanding Shares28,359,000Free FloatN/AMarket Cap$73.73 million OptionableNot Optionable Beta1.02 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesLudwig LutterChief Financial OfficerPamela KeckInvestor Relations ContactKey CompetitorsvTv TherapeuticsNASDAQ:VTVTCue BiopharmaNASDAQ:CUEAssembly BiosciencesNASDAQ:ASMBCorvus PharmaceuticalsNASDAQ:CRVSYS BiopharmaNASDAQ:YSView All Competitors BFRA Stock Analysis - Frequently Asked Questions How were Biofrontera's earnings last quarter? Biofrontera AG (NASDAQ:BFRA) announced its quarterly earnings results on Wednesday, November, 24th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The company earned $6.34 million during the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND). When did Biofrontera IPO? Biofrontera (BFRA) raised $18 million in an initial public offering on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. This page (NASDAQ:BFRA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
